Lapatinib
别名: GSK572016, GW2016
中文名称:拉帕替尼
目录号:S2111 Purity: 99.95%
Lapatinib 是一种有效的EGFR和ErbB2抑制剂,在无细胞试验中IC50分别为10.2和9.8 nM。Lapatinib 可诱导 ferroptosis 和细胞自噬。
CAS: 231277-92-2
客户使用Selleck的Lapatinib发表文献475篇
- Drug Resist Updat, 2024 73:101066
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Cell Metab, 2022 34(1):90-105.e7
- Cancer Discov, 2022 12(1):204-219
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Gut, 2021 70(5):890-899
- Nat Cell Biol, 2021 23(4):377-390
- Cell Res, 2020 10.1038/s41422-020-00409-1
- Cancer Cell, 2019 10.1016/j.ccell.2019.09.001
- Nat Cell Biol, 2019 21(8):1027-1040
- Nat Med, 2018 24(5):638-646
- Cancer Cell, 2018 34(6):922-938
- Cancer Cell, 2018 33(5):922-936
- Cancer Cell, 2018 34(1):148-162
- Nat Med, 2017 23(10):1167-1175
- Mol Cancer, 2017 16(1):34
- Cancer Discov, 2017 7(6):630-651
- Nature, 2016 538(7626):477-482
- Cancer Discov, 2016 6(8):838-851
- Gut, 2016 1296-305
- Blood, 2016 127(2):221-32
- Cancer Cell, 2015 27(3):397-408
- Mol Cancer, 2015 14:72
- Cancer Discov, 2015 5(8):832-41
- Cancer Discov, 2015
- Nat Med, 2014 20(9):1027-34
- Cancer Discov, 2013 3(5):520-33
- Cancer Cell, 2012 21(4):488-503
- J Extracell Vesicles, 2024 13(7):e12494
- Exp Mol Med, 2024 56(11):2382-2394
- Cancer Lett, 2024 593:216968
- Cell Rep, 2024 43(9):114710
- Cell Commun Signal, 2024 22(1):611
- Mol Oncol, 2024 10.1002/1878-0261.13749
- Oncogenesis, 2024 13(1):30
- Front Cell Infect Microbiol, 2024 14:1367938
- Am J Cancer Res, 2024 14(3):1087-1100
- Cancers (Basel), 2024 16(12)2253
- Transl Oncol, 2024 49:102073
- Sci Rep, 2024 14(1):8200
- Hum Cell, 2024 10.1007/s13577-024-01054-1
- Heliyon, 2024 10(17):e37085
- Open Vet J, 2024 14(5):1259-1268
- World J Oncol, 2024 15(3):492-505
- Cell Genom, 2024 4(2):100487
- World J Oncol, 2024 15(2):192-208
- Cancer Res Commun, 2024 10.1158/2767-9764.CRC-24-0221
- Nat Commun, 2023 14(1):3469
- Nat Commun, 2023 14(1):5035
- J Exp Clin Cancer Res, 2023 42(1):25
- J Immunother Cancer, 2023 11(6)e007117
- Cell Death Dis, 2023 14(8):532
- NPJ Precis Oncol, 2023 7(1):107
- Biomed Pharmacother, 2023 161:114527
- Breast Cancer Res, 2023 25(1):1
- Breast Cancer Res, 2023 25(1):51
- Cell Oncol (Dordr), 2023 10.1007/s13402-023-00769-x
- Int J Mol Sci, 2023 24(5)4350
- Int J Mol Sci, 2023 24(7)6228
- Sci Rep, 2023 13(1):22648
- Cancer Med, 2023 10.1002/cam4.6607
- J Cancer, 2023 14(18):3477-3495
- Braz J Med Biol Res, 2023 55:e12206
- bioRxiv, 2023 2023.03.10.531983
- Biochem Biophys Rep, 2023 34:101436
- Nat Commun, 2022 13(1):6481
- Nat Chem Biol, 2022 10.1038/s41589-022-00984-x
- Cell Rep Med, 2022 3(1):100492
- Cancer Res, 2022 canres.4145.2021
- Cancer Res, 2022 can.21.2908
- Cancer Lett, 2022 554:216024
- Cell Rep, 2022 41(11):111827
- Breast Cancer Res, 2022 24(1):18
- Cell Oncol (Dordr), 2022 45(4):601-619
- Mol Oncol, 2022 10.1002/1878-0261.13318
- iScience, 2022 25(10):105182
- Mol Cancer Ther, 2022 molcanther.0320.2021
- Cancer Sci, 2022 10.1111/cas.15617
- Cancer Sci, 2022 113(9):3193-3210
- Mol Cancer Ther, 2022 21(5):751-761
- Int J Mol Sci, 2022 23(14)7774
- Front Pharmacol, 2022 13:1032975
- Int J Mol Sci, 2022 23(2)775
- Int J Mol Sci, 2022 23(10)5476
- J Cell Mol Med, 2022 10.1111/jcmm.17210
- Cancers (Basel), 2022 14(6)1537
- Cancers (Basel), 2022 14(3)739
- Cancers (Basel), 2022 14(19)4883
- Front Mol Biosci, 2022 9:952651
- J Pers Med, 2022 12(2)258
- Biomedicines, 2022 10(11)2906
- Front Oncol, 2022 12:813100
- JCO Precis Oncol, 2022 6:e2100325
- Sci Rep, 2022 12(1):2928
- Sci Rep, 2022 12(1):2711
- Pharmacol Rep, 2022 10.1007/s43440-022-00396-7
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- BMC Cancer, 2022 22(1):844
- Mol Immunol, 2022 153:135-145
- Oncol Lett, 2022 23(6):177
- Sci Adv, 2022 8(2):eabh3375
- Johns Hopkins University, 2022
- Nat Commun, 2021 12(1):2940
- Nat Commun, 2021 12(1):6667
- Nat Commun, 2021 12(1):4566
- Mol Cell, 2021 81(4):708-723.e5
- Mol Psychiatry, 2021 10.1038/s41380-021-01137-7
- Clin Transl Med, 2021 11(11):e589
- Cancer Lett, 2021 527:10-23
- Cell Death Dis, 2021 12(6):588
- Cell Rep, 2021 34(10):108822
- Cell Rep, 2021 35(8):109181
- Eur J Cancer, 2021 145:92-108
- J Transl Med, 2021 19(1):184
- Breast Cancer Res, 2021 23(1):81
- Ecotoxicol Environ Saf, 2021 208:111693
- NPJ Breast Cancer, 2021 7(1):51
- NPJ Breast Cancer, 2021 7(1):79
- Int J Mol Sci, 2021 22(20)11199
- BMC Biol, 2021 19(1):228
- Cancers (Basel), 2021 13(14)3635
- Front Oncol, 2021 11:750852
- Sci Rep, 2021 11(1):10893
- Environ Toxicol, 2021 10.1002/tox.23125
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Cancer Med, 2021 10(7):2370-2379
- Drug Metab Dispos, 2021 49(1):53-61
- BMC Cancer, 2021 21(1):923
- Biochem Biophys Res Commun, 2021 567:154-160
- J Pharmacokinet Pharmacodyn, 2021 10.1007/s10928-020-09732-x
- Sci Adv, 2021 7(7)eabd7459
- Nat Struct Mol Biol, 2020 27(1):92-104
- Nat Commun, 2020 11(1):385
- Nat Commun, 2020 11(1):4370
- Nat Commun, 2020 11(1):5878
- Nat Commun, 2020 25;11(1):1556
- Adv Sci (Weinh), 2020
- Acta Neuropathol, 2020 139(6):1071-1088
- Clin Cancer Res, 2020 clincanres.2769.2020
- EMBO Mol Med, 2020 8;12(5):e11498
- EMBO Mol Med, 2020 12(8):e11987
- Cell Syst, 2020 10(3):240-253
- Cell Rep, 2020 31(13):107840
- Oncogene, 2020 10.1038/s41388-020-01481-y
- Transl Res, 2020 S1931-5244(20)30257-7
- Elife, 2020 2;9:e54954
- Antiviral Res, 2020 178:104790
- Breast Cancer Res, 2020 22(1):84
- Sci Signal, 2020 13(636):eaay1451
- NPJ Breast Cancer, 2020 6:30
- Mol Cancer Ther, 2020 molcanther.0259.2020
- Int J Mol Sci, 2020 18;21(8):2825
- Front Cell Dev Biol, 2020
- Cancers (Basel), 2020 27;12(5)pii: E1087
- Cancers (Basel), 2020 13;12(2) pii: E436
- Cancers (Basel), 2020 12(11)E3216
- Biochim Biophys Acta Mol Cell Res, 2020 1868(1):118892
- Neoplasia, 2020 22(11):576-589
- Neoplasia, 2020 22(10):470-483
- J Biol Chem, 2020 jbc.RA120.014960
- Biomedicines, 2020 8(12)E624
- Sci Rep, 2020 10(1):17768
- Sci Rep, 2020 10(1):21985
- Molecules, 2020 8;25(9) pii: E2220
- Cancer Res Treat, 2020 10.4143/crt.2020.585
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Biochem J, 2020 477(17):3329-3347
- PLoS One, 2020 15(1):e0227261
- PLoS One, 2020 4;15(5):e0231894
- J Cancer Res Clin Oncol, 2020 146(3):605-619
- SLAS Discov, 2020 2;2472555220929291
- Biol Open, 2020 9(1)
- Sci Adv, 2020 6(43)eabc3175
- Cancer Drug Resist, 2020 3(3):603-612
- Clin Cancer Res, 2019 25(5):1639-1649
- Clin Cancer Res, 2019 25(2):641-651
- Clin Cancer Res, 2019 1;25(19):5866-5877
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-18-3440
- J Exp Clin Cancer Res, 2019 38(1):236
- Cancer Res, 2019 10.1158/0008-5472.CAN-19-1555
- EBioMedicine, 2019 47:184-194
- Cell Rep, 2019 26(1):65-78
- Cell Commun Signal, 2019 17(1):15
- Cell Mol Life Sci, 2019 76(6):1185-1199
- Oncogene, 2019 38(11):1936-1950
- NPJ Precis Oncol, 2019 3:18
- Breast Cancer Res, 2019 21(1):77
- Cell Death Discov, 2019 5:153
- Int J Cancer, 2019 145(3):748-762
- Cells, 2019 8(12)
- Front Pharmacol, 2019 10:1116
- Oncotarget, 2019 10(23):2320-2334
- Int J Oncol, 2019 54(5):1555-1566
- Eur J Pharmacol, 2019 850:97-108
- Neuropharmacology, 2019 148:31-39
- Cell Cycle, 2019 18(13):1513-1522
- Biosci Rep, 2019 39(8)
- Biosci Rep, 2019 39(3)
- BMC Cancer, 2019 19(1):1044
- Front Genet, 2019 10:25
- PLoS One, 2019 14(6):e0217399
- Exp Dermatol, 2019 10.1111/exd.14010
- Bioorg Med Chem Lett, 2019 29(11):1282-1290
- Endocr J, 2019 66(6):515-522
- Anticancer Res, 2019 39(5):2377-2383
- Anticancer Res, 2019 39(7):3785-3793
- Nucleic Acids Res, 2018 46(10):5029-5049
- Nat Chem Biol, 2018 14(8):768-777
- Theranostics, 2018 8(12):3176-3188
- Clin Cancer Res, 2018 24(16):3928-3940
- Clin Cancer Res, 2018 24(23):6066-6077
- J Exp Clin Cancer Res, 2018 37(1):31
- Cancer Res, 2018 78(7):1845-1858
- Cancer Res, 2018 78(15):4396-4410
- EMBO Mol Med, 2018 10(9)
- PLoS Biol, 2018 16(12):e2006660
- Cell Syst, 2018 6(3):343-354
- Oncogene, 2018 37(12):1576-1593
- Breast Cancer Res, 2018 20(1):151
- Sci Signal, 2018 11(549)
- Mol Cancer Ther, 2018 17(10):2217-2225
- Mol Cancer Ther, 2018 17(9):2024-2033
- J Cell Physiol, 2018 233(3):2067-2074
- Front Pharmacol, 2018 9:861
- Int J Mol Sci, 2018 19(10)
- Oncotarget, 2018 9(26):18254-18268
- Oncotarget, 2018 9(73):33762-33777
- Lung Cancer, 2018 126:72-79
- Cancers (Basel), 2018 10.3390/cancers10090335
- Cancers (Basel), 2018 10(6)
- Mol Cancer Res, 2018 16(4):599-609
- Transl Oncol, 2018 11(6):1406-1418
- Sci Rep, 2018 8(1):84
- Sci Rep, 2018 8(1):6150
- Sci Rep, 2018 8(1):9991
- Ann Thorac Surg, 2018 105(2):363-370
- Sci Rep, 2018 8(1):3606
- Cell Biol Int, 2018 42(7):781-793
- Endocr Relat Cancer, 2018 25(4):471-480
- Drug Metab Dispos, 2018 46(6):779-785
- BMB Rep, 2018 51(12):660-665
- Mol Med Rep, 2018 18(1):958-964
- Metallomics, 2018 10(8):1141-1159
- Cancer Manag Res, 2018 10:6571-6579
- Biochem Biophys Res Commun, 2018 505(1):187-193
- Oncol Lett, 2018 15(1):235-242
- Urology, 2018 112:225.e1-225.e7
- Vet Comp Oncol, 2018 16(4):642-649
- Adv Biol Regul, 2018 67:190-211
- Nat Commun, 2017 8;8:15617
- Nat Commun, 2017 1;8(1):1232
- Nat Commun, 2017 8:14797
- Nat Commun, 2017 8(1):823
- Cancer Res, 2017 77(20):5554-5563
- Proc Natl Acad Sci U S A, 2017 114(15):E3129-E3138
- Cell Death Dis, 2017 8(8):e2980
- Oncogene, 2017 36(17):2394-2404
- Oncogene, 2017 36(48):6691-6700
- Breast Cancer Res, 2017 19(1):127
- Breast Cancer Res, 2017 19(1):74
- Arch Toxicol, 2017 91(8):2921-2938
- Cancer Immunol Immunother, 2017 66(7):865-876
- Mol Cancer Ther, 2017 16(2):357-364
- Mol Cancer Ther, 2017 16(6):1054-1067
- Mol Cancer Ther, 2017 16(4):681-693
- J Mol Biol, 2017 429(14):2211-2230
- Oncotarget, 2017 8(42):72281-72301
- Oncotarget, 2017 8(38):63901-63910
- Oncotarget, 2017 8(62):104894-104912
- Oncotarget, 2017 8(17):28971-28989
- Oncotarget, 2017 8(41):70736-70751
- Oncotarget, 2017 8(3):4277-4288
- Oncotarget, 2017 8(55):93688-93703
- Oncotarget, 2017 8(3):5003-5015
- Oncotarget, 2017 8(52):90262-90277
- Oncotarget, 2017 8(46):80804-80819
- Oncotarget, 2017 8(35):58918-58933
- Oncotarget, 2017 8(13):20961-20973
- Oncotarget, 2017 8(47):81776-81793
- Oncotarget, 2017 8(58):98771-98781
- Oncotarget, 2017 8(61):103167-103181
- Oncotarget, 2017 8(54):92240-92253
- Am J Cancer Res, 2017 7(7):1476-1485
- Am J Cancer Res, 2017 7(3):383-404
- Mol Pharm, 2017 14(10):3558-3567
- Mol Pharm, 2017 14(7):2368-2377
- J Biol Chem, 2017 292(2):748-759
- Carcinogenesis, 2017 38(11):1063-1072
- Sci Rep, 2017 7(1):3091
- Sci Rep, 2017 7(1):3964
- Sci Rep, 2017 7:42604
- Mol Carcinog, 2017 56(1):106-117
- Cell Cycle, 2017 16(16):1515-1525
- J Steroid Biochem Mol Biol, 2017 167:115-125
- Curr Med Chem, 2017 24(26):2860-2886
- Chem Res Toxicol, 2017 30(5):1219-1229
- Chin J Cancer, 2017 36(1):63
- BMC Cancer, 2017 17(1):535
- PLoS One, 2017 12(4):e0175977
- J Appl Toxicol, 2017 37(3):382-390
- SLAS Discov, 2017 22(7):915-922
- Biochemistry, 2017 56(34):4449-4456
- Breast Cancer (Dove Med Press), 2017 9:383-392
- Anticancer Drugs, 2017 28(10):1141-1149
- Tumour Biol, 2017 39(3):1010428317695028
- Integr Biol (Camb), 2017 9(12):912-924
- Nat Commun, 2016 7:13567
- Nat Commun, 2016 7:10880
- Nat Chem Biol, 2016 12(11):923-930
- Nat Chem Biol, 2016 12(7):531-8
- Genome Biol, 2016 17:80
- Clin Cancer Res, 2016 22(19):4859-4869
- Clin Cancer Res, 2016 22(24):6031-6038
- Clin Cancer Res, 2016 22(16):4197-205
- Cancer Res, 2016 pii: canres.3393
- Cancer Res, 2016 76(8):2432-42
- Cancer Res, 2016 76(4):974-83
- Oncogene, 2016 10.1038/onc.2016.109
- Oncogene, 2016 35(27):3587-97
- Oncogene, 2016 35(28):3681-91
- Elife, 2016 10.7554/eLife.17635
- Elife, 2016 10.7554/eLife.18489
- Breast Cancer Res, 2016 18(1):80
- J Transl Med, 2016 14:46
- Sci Signal, 2016 9(455):ra114
- Matrix Biol, 2016 55:22-34
- Eur J Med Chem, 2016 124:583-607
- Open Biol, 2016 6(4):150231
- Mol Cancer Ther, 2016 15(10):2508-2520
- Mol Cancer Ther, 2016 15(8):1988-97
- Mol Cancer Ther, 2016
- J Cell Physiol, 2016 231(5):1097-105
- Oncotarget, 2016 7(12):13706-16
- Oncotarget, 2016 7(40):65627-65642
- Oncotarget, 2016 7(23):34453-71
- Oncotarget, 2016 7(14):17290-300
- Oncotarget, 2016 8(31):50570-50581
- Oncotarget, 2016 7(12):14693-707
- Oncotarget, 2016 7(47):77291-77305
- Oncotarget, 2016 7(51):84556-84574
- Oncotarget, 2016 7(24):36865-36884
- Oncotarget, 2016 7(24):36138-36153
- Oncotarget, 2016 7(10):11539-52
- Oncotarget, 2016 7(44):71696-71702
- Oncotarget, 2016 7(26):40398-40417
- Oncotarget, 2016 7(50):83424-83436
- Oncotarget, 2016 7(18-:25983-6002
- Oncotarget, 2016 7(44):71790-71801
- Oncotarget, 2016 7(19):27778-86
- Oncotarget, 2016 7(6):7055-65
- Oncotarget, 2016 7(39):63924-63936
- Oncotarget, 2016 7(18):26551-66
- Oncotarget, 2016 7(2):1598-607
- ACS Infect Dis, 2016 2(7):518-28
- ACS Infect Dis, 2016 2(3):180-186
- Mol Pharm, 2016 13(3):784-94
- Am J Physiol Lung Cell Mol Physiol, 2016 311(2):L364-74
- Biochim Biophys Acta, 2016 1859(11):1449-1458
- PLoS Comput Biol, 2016 12(4):e1004827
- Oncol Rep, 2016 36(5):3058-3064
- Oncol Rep, 2016 36(5):2526-2534
- J Immunother, 2016 39(3):117-26
- BMC Cancer, 2016 16(1):813
- Biol Chem, 2016 397(7):671-8
- PLoS One, 2016 11(4):e0153025
- Biochem Biophys Res Commun, 2016 477(2):222-8
- Cancer Genet, 2016 209(4):119-29
- Sci Transl Med, 2015 7(284):284ra57
- Nat Commun, 2015 6:8481
- Clin Cancer Res, 2015 21(20):4597-606
- Clin Cancer Res, 2015 21(9):2115-26
- Cancer Res, 2015 75(2):394-404
- Cancer Res, 2015 75(24):5341-54
- Cancer Res, 2015 10.1158/0008-5472.CAN-15-0370
- Proc Natl Acad Sci U S A, 2015 112(17):E2149-55
- Proc Natl Acad Sci USA, 2015
- Cell Death Dis, 2015 6:e1771
- Cell Death Dis, 2015 6:e1699
- Cell Commun Signal, 2015 13:26
- Oncogene, 2015 34(41):5277-87
- Oncogene, 2015 34(9):1160-73
- Elife, 2015
- Sci Signal, 2015 8(401):ra111
- Sci Signal, 2015 8(378):ra52
- Mol Oncol, 2015 9(3):586-600
- J Invest Dermatol, 2015 135(12):3115-3124
- Mol Cancer Ther, 2015 14(8):1805-15
- J Cell Physiol, 2015 230(9):2281-98
- J Cell Physiol, 2015 230(1):131-9
- Oncotarget, 2015 9(38):24914-24926
- Oncotarget, 2015 6(19):17491-500
- Oncotarget, 2015 6(31):31628-39
- Oncotarget, 2015 6(4):2009-22
- Oncotarget, 2015 6(31):31272-83
- Oncotarget, 2015 6(36):38854-65
- Oncotarget, 2015 6(28):26230-41
- Oncotarget, 2015 6(27):24436-47
- Oncotarget, 2015
- Oncotarget, 2015
- Oncotarget, 2015 6(4):1967-80
- Oncotarget, 2015 6(7):5118-33
- Oncotarget, 2015
- Virulence, 2015 6(5):487-503
- Int J Oncol, 2015 46(3):1214-24
- Int J Oncol, 2015 47(2):499-505
- J Biol Chem, 2015 290(35):21705-12
- Eur J Pharm Sci, 2015 80:56-65
- Cell Cycle, 2015 14(7):1059-69
- Oncol Rep, 2015
- Biochem J, 2015 465(2):271-9
- Drug Metab Dispos, 2015 43(12):1934-7
- PLoS One, 2015 10(7):e0133219
- PLoS One, 2015 10(8):e0134426
- Mol Pharmacol, 2015 87(4):572-81
- Cancer Biol Ther, 2015 16(3):402-11
- Cancer Biol Ther, 2015 16(10):1535-47
- Cancer Biol Ther, 2015 16(11):1660-70
- Mol Biol Cell, 2015 26(22):4109-23
- J Proteomics, 2015 127(Pt B):259-63
- Org Biomol Chem, 2015 13(17):5006-11
- Chem Biol Drug Des, 2015 85(6):702-714
- Pancreas, 2015 44(1):152-7
- Thorac Cancer, 2015 6(6):695-703
- Thoracic Cancer, 2015 6(6):695-703
- Biomarkers, 2015
- Anticancer Drugs, 2015 26(4):422-7
- Anticancer Res, 2015 35(12):6685-93
- Cancer Res, 2014 10.1158/0008-5472.CAN-14-0844
- Proc Natl Acad Sci USA, 2014 109(17):6584-9
- Cancer Lett, 2014 342(1):82-91
- Cell Death Dis, 2014 5:e980
- Cell Rep, 2014 8(4):1037-48
- Oncogene, 2014 10.1038/onc.2014.161.
- Oncogene, 2014 10.1038/onc.2014.106.
- Oncogene, 2014
- Oncogene, 2014
- Oncogene, 2014
- Elife, 2014 3:e02523
- Breast Cancer Res, 2014 16(3):R45
- Br J Pharmacol, 2014 171(24):5757-73
- Oncotarget, 2014 5(15):5908-19
- Antimicrob Agents Chemother, 2014 10.1128/AAC.02393-14
- Drug Metab Dispos, 2014 42(3):318-22
- Drug Metab Dispos, 2014 42(11):1851-7
- PLoS One, 2014 9(9):e106349
- PLoS One, 2014 9(10):e111146
- J Mol Endocrinol, 2014 52(2):223-34
- Genes Cancer, 2014 5(7-8):261-72
- Genom Data, 2014
- J Clin Invest, 2013 123(5):2155-68
- Neuro Oncol, 2013 10.1093/neuonc/not152
- Nat Chem Biol, 2013 9(11):677-84
- Nat Chem Biol, 2013 9(5):307-12
- Cancer Lett, 2013 340(1):43-50
- Sci Signal, 2013
- Mol Cancer Ther, 2013
- Oncotarget, 2013
- Cell Cycle, 2013
- Mol Pharmacol, 2013 83(4):882-93
- Invest New Drugs, 2013 31(6):1458-65
- J Genet Syndr Gene Ther, 2013 4
- Genetic Syndromes & Gene Therapy, 2013 4:6
- Tumour Biol, 2013 34(2):1161-70
- ACS Nano, 2012 6(10):8525-35
- Mol Oncol, 2012 7(3):392-401
- Mol Carcinog, 2012 52(12):959-69
- PLoS One, 2012 7(5):e36691
- PloS one, 2012 10.1371/journal.pone.0036690
- Prostate, 2012 72(10):1140-9
- Mol Cancer Ther, 2011 10(4):697-707
- Anticancer Res, 2011 31(11):3767-73
- J Clin Invest, 2010
- Carcinogenesis, 2010 31(11):1948-55
化学信息&溶解度
分子量 | 581.06 |
分子式 | C29H26ClFN4O4S |
CAS号 | 231277-92-2 |
Smiles | CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 172.09 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 172.09 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 172.09 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。